Ivabradine in children with postural orthostatic tachycardia syndrome: a retrospective study

Abstract

<jats:title>Abstract</jats:title><jats:sec id="S1047951120001341_as1" sec-type="other"><jats:title>Background:</jats:title><jats:p>Ivabradine is a unique medication that reduces the intrinsic heart rate by specifically blocking the inward funny current that controls the pacemaker activity of the sinus node. We conducted a retrospective cohort study to assess the efficacy of ivabradine in children suffering from postural orthostatic tachycardia syndrome.</jats:p></jats:sec><jats:sec id="S1047951120001341_as2" sec-type="other"><jats:title>Methods:</jats:title><jats:p>A chart review was conducted of patients less than 18 years of age who were diagnosed with postural orthostatic tachycardia syndrome who had received ivabradine as treatment from January 2015 to February 2019 at our institution. Twenty-seven patients (25 females, 92.5%) were identified for the study. The outcomes which were assessed included a change in the severity and frequency of symptoms, heart rate, and blood pressure before and after starting ivabradine.</jats:p></jats:sec><jats:sec id="S1047951120001341_as3" sec-type="other"><jats:title>Results:</jats:title><jats:p>There was an improvement in the symptoms of 18 (67%) out of 27 patients. The most notable symptom affected was syncope/presyncope with a reduction in 90%, followed by lightheadedness (85%) and fatigue (81%). The vital signs of the patients showed an overall significant lowering of the heart rate during sitting (89.7 ± 17.9 versus 73.2 ± 12.1; p-value &lt;0.05) and standing (100.5 ± 18.1 versus 80.9 ± 10.1; p-value &lt;0.05) without a significant change in the blood pressure. Two patients had visual disturbances (luminous phenomena). Severe bradycardia and excessive flushing were seen in two patients, respectively. Another one patient reported joint pain and fatigue.</jats:p></jats:sec><jats:sec id="S1047951120001341_as4" sec-type="other"><jats:title>Conclusion:</jats:title><jats:p>This study indicates that 67% of children treated with ivabradine report an improvement in symptoms.</jats:p></jats:sec>